The abstract is read at the publisher; the summary is JClub's.
MAPK14 (p38α) is a prominent, context-dependent dependency in gilteritinib-resistant FLT3-mutated acute myeloid leukemia cells, linked to sustained resistance.
- Why it matters: Resistance to FLT3 inhibitors limits treatment, and MEK/ERK blockade shows limited benefit after resistance emerges, implying alternative signaling dependencies under drug pressure.
- What they did: An unbiased kinome-wide CRISPR-Cas9 screen in gilteritinib-resistant AML cells identified MAPK14 over MAPK3/MAPK1, and p38 inhibition or genetic impairment increased gilteritinib sensitivity and synergized with FLT3 inhibition.
- The result: Resistant cells show adaptor-mediated FLT3 rewiring where p46-SHC1 supports an FLT3-associated MKK3/6–p38 module despite FLT3 inhibition, sustaining downstream programs including MYC and supporting survival under prolonged drug exposure.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.